Truemeds Secures Rs 375.2 Crore in Series C Funding

The telehealth platform Truemeds is successfully raising Rs 375.2 crore (approximately $44 million) through its Series C funding round. This round is spearheaded by Accel India, with additional contributions from WestBridge and Info Edge.

According to regulatory filings obtained from the Registrar of Companies (RoC), Truemeds’ board has approved a special resolution allowing the issuance of 1 equity share and 49,300 Series C preference shares at a price of Rs 76,110 each to secure the intended amount.

Accel India plans to invest Rs 285.4 crore, while WestBridge, through its investment vehicles Konark and MMPL Trust, is set to contribute Rs 68.49 crore. Info Edge will also participate with an injection of Rs 21.31 crore.

Proceeds from this funding will be allocated to propelling business growth and executing future plans, as indicated in the company’s filings. Startup Superb estimates that Truemeds will reach a valuation of approximately $340 million on a post-money basis.

With this latest funding, Accel India is expected to hold around 10% of Truemeds, while WestBridge and Info Edge will command stakes of 28.64% and 23.02%, respectively. Co-founders Akshat Nayyar and Kunal Wani will retain a combined 22.43% stake in their personal capacity.

Truemeds’ Unique Business Model

Established by Nayyar and Wani, Truemeds enables consumers to source alternative brand medicines by uploading their prescriptions.

Financial Performance

Truemeds experienced a remarkable two-fold increase in revenue, reaching Rs 315 crore during the fiscal year that concluded in March 2024. Effective cost management and scaling strategies have also led to a 9% decrease in losses, reducing them to Rs 61 crore in the same timeframe.

Market Challenges and Opportunities

In India, awareness around generic medicines is advancing rapidly, primarily due to government initiatives aimed at providing cost-effective medications at both state and national levels. While this trend has created a marketplace for consumers seeking alternatives beyond prescribed options, it also poses a significant challenge for Truemeds. If government initiatives are successful, they may impede growth in many high-volume segments. Nonetheless, targeted government efforts are focused on specific, commonly used molecules, which allows companies like Truemeds to leverage the increased awareness of alternatives. This appears to underpin the rationale behind the recent funding.

Truemeds has curated a broad range of options for customers searching for more affordable alternatives, encompassing everything from vitamins and supplements to homeopathic medicines. However, competition remains fierce, with government-supported pharmacies and private establishments both adapting to the evolving market landscape.